Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025
Jazz Pharmaceuticals (NASDAQ: JAZZ), a global biopharma company, has announced it will release its 2025 second quarter financial results on Tuesday, August 5, 2025, after U.S. market close. The company will host a live audio webcast at 4:30 p.m. EDT / 9:30 p.m. IST to discuss the results and provide business updates.
Participants are encouraged to register at least 15 minutes before the webcast through the company's website or direct registration link. A replay will be available in the Investors section of Jazz Pharmaceuticals' website. The company specializes in developing medicines for sleep disorders, epilepsy, and cancer treatments, with operations spanning multiple countries.
Jazz Pharmaceuticals (NASDAQ: JAZZ), un'azienda biofarmaceutica globale, ha annunciato che pubblicher脿 i risultati finanziari del secondo trimestre 2025 marted矛 5 agosto 2025, dopo la chiusura del mercato statunitense. La societ脿 terr脿 una webcast audio dal vivo alle 16:30 EDT / 21:30 IST per discutere i risultati e fornire aggiornamenti aziendali.
Si invita i partecipanti a registrarsi almeno 15 minuti prima della diretta tramite il sito web della societ脿 o il link diretto di registrazione. Una replica sar脿 disponibile nella sezione Investitori del sito di Jazz Pharmaceuticals. L'azienda 猫 specializzata nello sviluppo di farmaci per disturbi del sonno, epilessia e trattamenti oncologici, con attivit脿 in diversi paesi.
Jazz Pharmaceuticals (NASDAQ: JAZZ), una compa帽铆a biofarmac茅utica global, ha anunciado que publicar谩 sus resultados financieros del segundo trimestre de 2025 el martes 5 de agosto de 2025, despu茅s del cierre del mercado estadounidense. La empresa realizar谩 una transmisi贸n en vivo por audio a las 4:30 p.m. EDT / 9:30 p.m. IST para discutir los resultados y ofrecer actualizaciones comerciales.
Se recomienda a los participantes registrarse al menos 15 minutos antes de la transmisi贸n a trav茅s del sitio web de la compa帽铆a o mediante un enlace directo de registro. Una repetici贸n estar谩 disponible en la secci贸n de Inversores del sitio web de Jazz Pharmaceuticals. La empresa se especializa en el desarrollo de medicamentos para trastornos del sue帽o, epilepsia y tratamientos contra el c谩ncer, operando en varios pa铆ses.
Jazz Pharmaceuticals (NASDAQ: JAZZ)電� 旮�搿滊矊 氚旍澊鞓れ牅鞎� 須岇偓搿滌劀 2025雲� 2攵勱赴 鞛 鞁れ爜鞚� 2025雲� 8鞗� 5鞚� 頇旍殧鞚� 氙戈淡 鞁滌灔 毵堦皭 頉勳棎 氚滍憸頃� 鞓堨爼鞛呺媹雼�. 須岇偓電� 鞓ろ泟 4鞁� 30攵� EDT / 鞓ろ泟 9鞁� 30攵� IST鞐� 鞁れ爜 氚滍憸 氚� 靷梾 鞐呺嵃鞚错姼毳� 鞙勴暅 霛检澊敫� 鞓る敂鞓� 鞗轨簮鞀ろ姼毳� 歆勴枆頃╇媹雼�.
彀胳劃鞛愲摛鞚� 鞗轨簮鞀ろ姼 鞁滌瀾 斓滌唽 15攵� 鞝勳棎 須岇偓 鞗轨偓鞚错姼雮� 歆侅爲 霌彪 毵來伂毳� 韱淀暣 霌彪頃� 瓴冹潉 甓岇灔頃╇媹雼�. 鞛癌靻§潃 Jazz Pharmaceuticals 韴瀽鞛� 靹轨厴鞐愳劀 鞚挫毄頃� 靾� 鞛堨姷雼堧嫟. 鞚� 須岇偓電� 靾橂┐ 鞛レ暊, 臧勳, 鞎� 旃橂鞝� 臧滊皽鞚� 鞝勲鞙茧 頃橂┌ 鞐煬 甑皜鞐愳劀 靷梾鞚� 鞖挫榿頃橁碃 鞛堨姷雼堧嫟.
Jazz Pharmaceuticals (NASDAQ: JAZZ), une entreprise biopharmaceutique mondiale, a annonc茅 qu'elle publiera ses r茅sultats financiers du deuxi猫me trimestre 2025 le mardi 5 ao没t 2025, apr猫s la cl么ture du march茅 am茅ricain. La soci茅t茅 organisera une webdiffusion audio en direct 脿 16h30 EDT / 21h30 IST pour discuter des r茅sultats et fournir des mises 脿 jour sur ses activit茅s.
Les participants sont invit茅s 脿 s'inscrire au moins 15 minutes avant la diffusion via le site web de l'entreprise ou un lien d'inscription direct. Une rediffusion sera disponible dans la section Investisseurs du site de Jazz Pharmaceuticals. L'entreprise est sp茅cialis茅e dans le d茅veloppement de m茅dicaments pour les troubles du sommeil, l'茅pilepsie et les traitements contre le cancer, avec des op茅rations dans plusieurs pays.
Jazz Pharmaceuticals (NASDAQ: JAZZ), ein globales Biopharma-Unternehmen, hat angek眉ndigt, seine Finanzergebnisse f眉r das zweite Quartal 2025 am Dienstag, den 5. August 2025, nach B枚rsenschluss in den USA zu ver枚ffentlichen. Das Unternehmen wird um 16:30 Uhr EDT / 21:30 Uhr IST ein Live-Audio-Webcast abhalten, um die Ergebnisse zu besprechen und Gesch盲ftsaktualisierungen zu geben.
Teilnehmer werden gebeten, sich mindestens 15 Minuten vor dem Webcast 眉ber die Website des Unternehmens oder einen direkten Registrierungslink anzumelden. Eine Aufzeichnung wird im Investor-Bereich der Jazz Pharmaceuticals-Website verf眉gbar sein. Das Unternehmen ist auf die Entwicklung von Medikamenten f眉r Schlafst枚rungen, Epilepsie und Krebsbehandlungen spezialisiert und ist in mehreren L盲ndern t盲tig.
- None.
- None.
Interested parties may register for the call in advance 聽or via the Investors section of the Jazz Pharmaceuticals website at . To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.
A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at .
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc聽(Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases 鈥� often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in聽Dublin, Ireland聽with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit聽聽for more information.
Contacts:
Investors:
Jack Spinks
Senior Director, Investor Relations
Jazz Pharmaceuticals plc
[email protected]
Ireland聽+353 1 634 3211
U.S.聽+1 650 496 2717
Media:
Kristin Bhavnani
Head of聽Global Corporate Communications
Jazz Pharmaceuticals plc
[email protected]
Ireland聽+353 1 637 2141
U.S.聽+1 215 867 4948
View original content to download multimedia:
SOURCE Jazz Pharmaceuticals plc
FAQ
When will Jazz Pharmaceuticals (JAZZ) report Q2 2025 earnings?
What time is Jazz Pharmaceuticals' Q2 2025 earnings call?
How can investors access Jazz Pharmaceuticals' Q2 2025 earnings call?
What are Jazz Pharmaceuticals' main business areas?
Where can investors find the replay of Jazz Pharmaceuticals' Q2 2025 earnings call?
